These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8587097)

  • 21. [The lack of awareness of the Israeli population regarding gastrointestinal complications from non-steroidal anti-inflammatory drugs].
    Zandman-Goddard G; Langevitz P
    Harefuah; 2001 Jun; 140(6):476-8, 567, 566. PubMed ID: 11420844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases.
    Lam J; Polifka JE; Dohil MA
    J Am Acad Dermatol; 2008 Aug; 59(2):295-315. PubMed ID: 18410980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai.
    Du W; Levine M; Wang L; Zhang Y; Yi C; Wang H; Wang X; Xie H; Xu J; Jin H; Wang T; Huang G; Wu Y
    Can J Clin Pharmacol; 2007; 14(1):e40-4. PubMed ID: 17237524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers.
    Shin YS; Lee YW; Choi YH; Park B; Jee YK; Choi SK; Kim EG; Park JW; Hong CS
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):910-5. PubMed ID: 19621345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
    Steinfeld S; Bjørke PA
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relative toxicity of alternative therapies for rheumatoid arthritis: implications for the therapeutic progression.
    Fries JF; Williams CA; Ramey DR; Bloch DA
    Semin Arthritis Rheum; 1993 Oct; 23(2 Suppl 1):68-73. PubMed ID: 8278821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index.
    Welch V; Singh G; Strand V; Fries J; Boers M; Ramey D; Day RO; Brooks P; Tugwell P; Clinch J; Kristjansson B
    J Rheumatol; 2001 May; 28(5):1188-91. PubMed ID: 11361211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COX-2 inhibitors and the heart: putting risk in perspective.
    Bobadilla RV; Barnett EM; Randels CL
    Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
    [No Abstract]   [Full Text] [Related]  

  • 31. Assessment and prevention of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs.
    Lane ME; Kim MJ
    J Pharm Pharmacol; 2006 Oct; 58(10):1295-304. PubMed ID: 17034651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Arthritis, Rheumatism and Aging Medical Information System (ARAMIS): still young at 30 years.
    Bruce B; Fries JF
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S163-7. PubMed ID: 16273801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing and understanding patient risk.
    Fries JF
    Scand J Rheumatol Suppl; 1992; 92():21-4. PubMed ID: 1574684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing the toxicity of two drugs in the framework of spontaneous reporting: a confidence interval approach.
    Tubert-Bitter P; Begaud B; Moride Y; Chaslerie A; Haramburu F
    J Clin Epidemiol; 1996 Jan; 49(1):121-3. PubMed ID: 8598505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mandatory pharmacovigilance.
    Maksymowych WP
    CMAJ; 2003 Mar; 168(6):672; discussion 672-3. PubMed ID: 12642413
    [No Abstract]   [Full Text] [Related]  

  • 36. ARAMIS (the American Rheumatism Association Medical Information System). A prototypical national chronic-disease data bank.
    Fries JF; McShane DJ
    West J Med; 1986 Dec; 145(6):798-804. PubMed ID: 3492816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A toxicity index for comparison of side effects among different drugs.
    Fries JF; Spitz PW; Williams CA; Bloch DA; Singh G; Hubert HB
    Arthritis Rheum; 1990 Jan; 33(1):121-30. PubMed ID: 2302262
    [No Abstract]   [Full Text] [Related]  

  • 38. Corrigendum to "The Glucocorticoid Toxicity Index: Measuring Change in Glucocorticoid Toxicity Over Time" [Seminars in Arthritis and Rheumatism 55 (2022):152010].
    Stone JH; McDowell PJ; Jayne DRW; Merkel PA; Robson J; Patel NJ; Zhang Y; Yue H; Bekker P; Heaney LG
    Semin Arthritis Rheum; 2024 Oct; 68():152496. PubMed ID: 38954998
    [No Abstract]   [Full Text] [Related]  

  • 39. Corrigendum to The Glucocorticoid Toxicity Index: Measuring Change in Glucocorticoid Toxicity Over Time [Seminars in Arthritis and Rheumatism Volume 55, 152010].
    Stone JH; McDowell PJ; Jayne DRW; Merkel PA; Robson J; Patel NJ; Zhang Y; Yue H; Bekker P; Heaney LG
    Semin Arthritis Rheum; 2023 Feb; 58():152124. PubMed ID: 36473338
    [No Abstract]   [Full Text] [Related]  

  • 40. A clinical and economic review of disease-modifying antirheumatic drugs.
    Gabriel SE; Coyle D; Moreland LW
    Pharmacoeconomics; 2001; 19(7):715-28. PubMed ID: 11548909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.